ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2022
Polyethylene Glycol-Like Brush Polymer Conjugate of a Protein Drug Does Not Induce an Antipolymer Immune Response and Has Enhanced Pharmacokinetics than Its Polyethylene Glycol Counterpart.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 64 citations in OpenAlex.
- Functional cyclic disulfides enable multi-pathway degradable polyvinyls.Chemical science · 2026Article
- Molecular Design of Thermoresponsive Poly(oligoethylene glycol)vinyl Esters for the Generation of Polymer Brush-Based Biointerfaces.ACS polymers Au · 2026Article
- Dynamic Arrest and Tunable Gelation of Immunogenically Inert POEGMA Nanoparticles.ACS polymers Au · 2026Article
- Antioxidant malic-acid-derived lipid nanoparticles delivering secretory uricase circRNA for hyperuricemia and complication management in mice.Nature communications · 2026Article
- A unimolecular GLP-1 and FGF21 dual agonist for treatment of metabolic dysfunction-associated steatohepatitis.Communications medicine · 2026Article
- Amylopectin Copolymers Grafted with RAFT-Obtained Synthetic Polymers: Synthesis and Aqueous Solution Behavior.Biomacromolecules · 2026Article
- Thermoreversibly assembled polymersomes for highly efficient loading, processing and delivery of protein and siRNA biologics.Nature biomedical engineering · 2026Article
- All-PEG-Like Block Copolymers Self-Assemble into Stealth Nanocarriers for Drug Delivery.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Overcoming PEG Antigenicity: Statistical PEG Isomers Reduce Antibody Binding.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- The evolution of nanomedicine: The rise of next-generation nanomaterials in cancer nanomedicine.Science advances · 2025Review
- Article
- Nanoparticles for Photodynamic Therapy of Breast Cancer: A Review of Recent Studies.Molecules (Basel, Switzerland) · 2025Review
- Emerging strategies against accelerated blood clearance phenomenon of nanocarrier drug delivery systems.Journal of nanobiotechnology · 2025Review
- Advances in drug delivery systems for the management of gout and hyperuricemia.Frontiers in pharmacology · 2025Review
- Nanocarriers for intracellular delivery of proteins in biomedical applications: strategies and recent advances.Journal of nanobiotechnology · 2024Review
- Programmability and biomedical utility of intrinsically-disordered protein polymers.Advanced drug delivery reviews · 2024Review
- The effect of comb length on theNanoscale advances · 2024Article
- Article
- Thermoresponsive Polypeptide Fused L-Asparaginase with Mitigated Immunogenicity and Enhanced Efficacy in Treating Hematologic Malignancies.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- RAFT Polymer-Antibody Conjugation: Squaramide Ester Chemistry Leads to Conjugates with a Therapeutic Anti-EGFR Antibody with Full Retention of Activity and Increased Tumor UptakeMolecular pharmaceutics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
Abstract
Protein therapeutics, except for antibodies, have a short plasma half-life and poor stability in circulation. Covalent coupling of polyethylene glycol (PEG) to protein drugs addresses this limitation. However, unlike previously thought, PEG is immunogenic. In addition to induced PEG antibodies, ≈70% of the US population has pre-existing anti-PEG antibodies. Both induced and preexisting anti-PEG antibodies result in accelerated drug clearance, reduced clinical efficacy, and severe hypersensitivity reactions that have limited the clinical utility of uricase, an enzyme drug for treatment for refractory gout that is decorated with a PEG corona. Here, the authors synthesize a poly(oligo(ethylene glycol) methyl ether methacrylate) (POEGMA) conjugate of uricase that decorates the protein with multiple polymer chains to create a corona to solve these problems. The resulting uricase-POEGMA is well-defined, has high bioactivity, and outperforms its PEG counterparts in its pharmacokinetics (PK). Furthermore, the conjugate does not induce anti-POEGMA antibodies and is not recognized by anti-PEG antibodies. These findings suggest that POEGMA conjugation may provide a solution to the immunogenicity and antigenicity limitations of PEG while improving upon its PK benefits. These results transcend uricase and can be applied to other PEGylated therapeutics and the broader class of biologics with suboptimal PK.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.